~~<i id='83ED77488A'><strike id='83ED77488A'><tt id='83ED77488A'><pre id='83ED77488A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：entertainment 2025-09-30 20:05:42 - browse：9

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The EU Joint Clinical Assessment needs to live up to its promise

focus

explore

focus

leisure time

focus

hotspot

MollyFergusonforSTATThenewsthattheweightlossdrugWegovyreducedtheriskofheartattacksandstrokesinoverwe

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

Former Pear Therapeutics executives start new VC firm

STAT Summit: How a Chicago ER doctor tackles gun violence

Beam Therapeutics to lay off 20% of its staff, re

California store owner shot dead in dispute over displaying Pride flag: Police

People can get long Covid without testing positive for virus: Study

entertainment

explore

focus

New air purifier tech could be key to improving indoor air quality

California store owner shot dead in dispute over displaying Pride flag: Police

At least 13 dead in Texas as scorching temps continue

Health officials lay out plans to cope with respiratory virus season

Medicare details structure of new drug price negotiation program

STAT Summit: GSK CEO on pharma giant's new direction

After affirmative action ruling, medical educators look to 'holistic review'

How climate

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Beam Therapeutics to lay off 20% of its staff, re

explore

Can U.S. cancer drug shortages be fixed?

Hospital price transparency does save money, advocate argues

FDA gives detailed accounting of AI

First Opinion Podcast: Long Covid needs a new approach

Vivek Ramaswamy made waves in the debate, much as in biotech

Wegovy improves function in certain heart failure patients

focus

leisure time

focus

hotspot